Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.78 |
| ▸ | RXRB | P28702 | 10/20 | 0.78 |
| ▸ | RXRG | P48443 | 10/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | MALT1 | Q9UDY8 | 6/20 | 0.57 |
| ▸ | RPA1 | P27694 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.54 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551695 | 1.00 | RXRA (0.78) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL9522392 | 0.90 | RXRA (0.81) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL5393447 | 0.86 | RXRA (0.84) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL6501484 | 0.85 | PTGS2 (0.74) | RXRARXRBRXRGPTGS2SMN1; SMN2 | |
| SCHEMBL14728118 | 0.82 | RXRA (0.80) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL14445463 | 0.80 | RXRA (0.78) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL8476180 | 0.79 | RXRA (0.57) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL9465697 | 0.79 | RXRA (0.61) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL878054 | 0.77 | RXRA (0.71) | RXRARXRBRXRGPTGS2ALOX5 | |
| SCHEMBL9520300 | 0.77 | ALOX5 (0.79) | RXRARXRBRXRGPTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | claimed |
| WO-2005037227-A2 | SELECTIVE COX-2 INHIBITORS | MICROBIA, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293542-A1 | Selective Cox-2 Inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| WO-2005037227-A2 | SELECTIVE COX-2 INHIBITORS | MICROBIA, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293542-A1 | Selective Cox-2 Inhibitors | PTGS2, FAAH2, PTGES2 | RXRA 3048/4885RXRB 2765/4885RXRG 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.